4.7 Review

Does diabetes prevention translate into reduced long-term vascular complications of diabetes?

期刊

DIABETOLOGIA
卷 62, 期 8, 页码 1319-1328

出版社

SPRINGER
DOI: 10.1007/s00125-019-4928-8

关键词

Cardiovascular disease; Cardiovascular disease risk factors; Diabetes prevention; Long-term diabetes complications; Microvascular disease; Review

资金

  1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health [U01 DK048489]
  2. NIDDK
  3. Indian Health Service
  4. National Institute of Child Health and Human Development
  5. National Institute on Aging
  6. National Eye Institute
  7. National Heart Lung and Blood Institute
  8. National Cancer Institute
  9. Office of Research on Women's Health
  10. National Institute on Minority Health and Health Disparities
  11. Centers for Disease Control and Prevention
  12. American Diabetes Association
  13. Bristol-Myers Squibb
  14. Parke-Davis
  15. McKesson BioServices Corp.
  16. Matthews Media Group, Inc.
  17. Henry M. Jackson Foundation
  18. DPP
  19. DPPOS
  20. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK075078] Funding Source: NIH RePORTER

向作者/读者索取更多资源

The global epidemic of type 2 diabetes has prompted numerous studies and public health efforts to reduce its development. A variety of interventions, including lifestyle modifications and pharmacological agents directed at ameliorating the major risk factors for type 2 diabetes, are of proven efficacy in reducing the development of type 2 diabetes in people with impaired glucose tolerance. While prevention of the hyperglycaemia characteristic of diabetes is arguably an important, clinically relevant outcome, a more compelling outcome with greater clinical significance is the prevention or reduction of the relatively diabetes-specific microvascular and less-specific cardiovascular disease (CVD) complications associated with diabetes. These complications cause the majority of morbidity and excess mortality associated with diabetes. Any reduction in diabetes should, logically, also reduce the occurrence of its long-term complications; however, most diabetes prevention trials have not been of sufficient duration to allow such an evaluation. The limited long-term data, largely from the Da Qing Diabetes Prevention Study (DQDPS) and the Diabetes Prevention Program (DPP) and their respective follow-up studies (DQDPOS and DPPOS), suggest a reduction in microvascular complications and amelioration of CVD risk factors. Only the DQDPOS and Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) studies have shown a reduction in CVD events and only DQDPOS has demonstrated a decrease in CVD and overall mortality. While these limited data are promising, whether diabetes prevention directly reduces complication-related morbidity and mortality remains unclear. Longer follow-up of prevention studies is needed to supplement the limited current clinical trial data, to help differentiate the effects of diabetes prevention itself from the means used to reduce diabetes development and to understand the balance among benefits, risks and costs of prevention.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据